Vivani Medical Inc. (VANI)

Over the past six months, Vivani Medical announced the pricing and closing of common stock offerings in January 2026, raising approximately $4.5 million. Insider buying activity was reported, and Cortigent presented positive results for its Orion Visual Cortical Prosthesis System. In November 2025, the company provided a business update and reported its third-quarter financial results, highlighting the successful completion of the LIBERATE-1 study and securing approximately $25.7 million in cash and commitments. In October 2025, Vivani Medical announced the closing and pricing of common stock offerings and withdrew the record date for the spin-off of Cortigent. In September 2025, Vivani Medical presented at the Emerging Growth Conference. The company's stock has experienced a -0.780% change over the past year, with a 52-week range between $0.905 and $1.920.

The provided information does not contain specific details regarding demand seasonality for Vivani Medical, Inc.'s products and services. Demand for such medical treatments is generally driven by disease prevalence and treatment efficacy rather than seasonal patterns.

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants using its NanoPortal™ platform to treat chronic diseases and address medication non-adherence. Its pipeline includes NPM-115 for chronic weight management, NPM-119 for type 2 diabetes, NPM-139 for chronic weight management with potential for less frequent dosing, NPM-133 for type 2 diabetes, and OKV-119 for metabolic diseases in cats. Through Cortigent, it is also developing implantable visual prostheses devices like the Orion Visual Cortical Prosthesis System for blind individuals.

Vivani Medical, Inc. is headquartered in Emeryville and Alameda, California, United States. The company conducted its first-in-human study (LIBERATE-1) for NPM-115 in Australia.

Vivani Medical's brand reputation has been positively influenced by the successful completion of the LIBERATE-1 study and Cortigent's presentation of promising results for the Orion Visual Cortical Prosthesis System. The company's ongoing equity offerings to fund its pipeline also demonstrate continued investment and commitment to its development programs.

Vivani Medical, Inc.'s ownership is a mix of institutional and individual investors. Approximately 5.61% of the company's stock is owned by institutional investors, while insiders hold about 47.41%. Major institutional owners include Vanguard Group Inc., Tanager Wealth Management LLP, Commonwealth Equity Services LLC, Geode Capital Management LLC, Connective Capital Management LLC, Wealthedge Investment Advisors LLC, Northern Trust Corp, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Monetary Management Group Inc, State Street Corp, CI Private Wealth, LLC and Evoke Wealth, Llc. Significant individual owners include Gregg Williams (41% of shares outstanding), Joachim & Yaeko Bolck Conservators For Yasuo Saito Bolck (6.9% of shares outstanding) and Adam Mendelsohn (5.1% of shares outstanding).